Clinical Trials Logo

Clinical Trial Summary

The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04925141
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status Completed
Phase Phase 4
Start date May 10, 2016
Completion date December 6, 2019

See also
  Status Clinical Trial Phase
Terminated NCT00644878 - Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Phase 2
Recruiting NCT06082804 - Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia N/A
Recruiting NCT05384587 - Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia Phase 2
Active, not recruiting NCT04666259 - Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation Phase 3
Recruiting NCT05794880 - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing N/A
Recruiting NCT03842696 - Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 1/Phase 2